Markus Sieger, CEO Polpharma Group, has been appointed to the position of Vice President of Medicines for Europe whose members represent the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries.
As member of Executive and Vice President, Markus Sieger will be working together with new President Elisabeth Stampa (Medichem) and Vice President Rebecca von Gunten (Sandoz) – on facilitating sustainable API and medicines manufacturing in the EU to secure affordable product supplies for patients, which are directly linked with the public health needs in Europe.
“Millions of European patients have and will benefit from better access to standard therapies because of the use of generic and biosimilar medicines today. Generic medicines have become the cornerstone of European healthcare drugs, proven by the recent COVID crisis. We have to secure that all essential medicines and API are produced here in Europe to secure access for years to come. Medicines for Europe and its activities are more important than ever. I will personally engage strongly into all aspects of digitalisation of the healthcare infrastructure, including the regulatory systems, e-leaflets etc. All in the interest of providing more affordable and better solutions to patients.”
Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added companies. As a leading partner for better healthcare, aim to increase the health and wellbeing of all Europeans through better access to high quality medicines. Medicines for Europe members’ portfolio cover 80% of therapy areas, and in so doing, safeguards the sustainability of Europe’s healthcare systems for future generations. Medicines for Europe’s ambition is fully aligned with the EU’s pharmaceutical and industrial strategy which shall be complemented by fast and efficient application of digital solutions both in medical care and health system management.
Medicines for Europe began over 20 years ago as the European Generics Medicines Association (EGA) with the goal of representing the emerging generic industry, and later growing to include biosimilar medicines to its portfolio.
See all members of Medicines for Europe: https://www.medicinesforeurope.com/medicines-for-europe/#section-5